TopStocks Alert: (Nasdaq: MDCX) Why MDCX Needs to Be on Your Radar Right Now and the 7 Catalysts Behind It
Hello Readers,
We are excited to share a brand new alert with you — one we have never brought to your attention before. Medicus Pharma Ltd. (Nasdaq: MDCX) has taken over our entire watchlist heading into what could be its most pivotal quarter yet.
Here's the short version: two clinical-stage drug candidates, Phase 2 data due any day, a fresh FDA clearance, $14 million in insider conviction at over 2.5x the current price, and a combined addressable market estimated at $8 billion. Trading at roughly $40 million market cap.
This company is developing a dissolvable microneedle patch that delivers chemotherapy directly into skin cancer tumors — no surgery, no scarring, no hospital visit. The company has stated it expects to release Phase 2 topline data from a 90-patient U.S. study before the end of Q1 2026.
Meanwhile, the FDA just cleared its second drug candidate — a next-generation prostate cancer treatment targeting an underserved population of men with high cardiovascular risk — to begin a new Phase 2b trial.
With 15.4% institutional ownership, analyst targets suggesting significant upside, and a Phase 2 data readout that could land before the end of this quarter — we wanted to make sure this was on your radar immediately.
Read the full breakdown below.
Medicus Pharma Ltd. (Nasdaq: MDCX)
Medicus Pharma Ltd. is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutic assets. The company is actively engaged in multiple countries across three continents, with clinical programs running in the United States, the United Kingdom, and the United Arab Emirates.
Based on a rapid-fire series of catalysts that have stacked up in just the last 90 days, (Nasdaq: MDCX) has pushed its way to the top of our radar:
- No. 1 — SkinJect Phase 2 Topline Data Due This Quarter — Interim Showed >60% Clearance.
- No. 2 — FDA Cleared Teverelix Phase 2b Trial For Advanced Prostate Cancer.
- No. 3 — Management Has Nearly $14 Million Of Personal Capital Committed At $4/Share.
- No. 4 — Micro-Cap With 15.4% Institutional Ownership And 6.4% Short Interest.
- No. 5 — Analyst Targets Average $23.50 — Significant Upside From Current Levels.
- No. 6 — Teverelix Royalty Cut To 2% Improves Partnering Appeal.
- No. 7 — Bloomberg, Nasdaq Bell, 6-Part Media Series — Visibility Is Accelerating.
But more on this in a moment...
Company Breakdown — Medicus Pharma Ltd. (Nasdaq: MDCX)
Medicus Pharma Ltd. specializes in identifying, acquiring, and advancing de-risked clinical-stage assets through clinical development and commercialization. The company currently operates two wholly owned subsidiaries — each targeting a significant, underserved market:
Source: Medicus Pharma Q4 2025 Corporate Presentation
About SkinJect — Medicus Pharma's (Nasdaq: MDCX) Lead Asset
A novel non-invasive regimen to treat skin cancer — especially Basal Cell Carcinoma.
SkinJect Inc., a wholly owned subsidiary of Medicus, is a development-stage biotechnology company focused on commercializing a novel treatment for non-melanoma skin cancer, especially basal cell carcinoma (BCC), using a patented dissolvable doxorubicin-containing microneedle array (D-MNA).
D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The relevant U.S. Patents were granted to the University of Pittsburgh and Carnegie Mellon University in 2018.
SkinJect secured exclusive worldwide development and commercialization rights from the University of Pittsburgh and Carnegie Mellon University in April 2016. The company aims to provide an alternative to an invasive, painful, but effective treatment commonly called Mohs Surgery — instead offering an efficacious, painless, and easy-to-administer treatment in a standard office setting.
The treatment consists of one topical application per week during a 30-minute office visit over three weeks. Minimal local irritation is anticipated. The estimated cost of 3 SkinJect microneedle patches is approximately US$1,000 — compared to Mohs surgery which ranges from US$2,000 to US$15,000 per the company's corporate presentation.
Key SkinJect Clinical Milestones:
- Phase 1 completed March 2021 — met primary safety and tolerability endpoint; 6 participants experienced complete response on histological examination.
- Phase 2 IND clinical protocol submitted to the FDA in January 2024 for a randomized, controlled, double-blind, multicenter study.
- Patient recruitment began August 2024 across 9 U.S. clinical sites.
- Positively trending interim analysis (March 2025) showed more than 60% complete clinical clearance after more than 50% of patients had been randomized.
- IRB approved increase in the number of patients from 60 to 90 (April 2025).
- FDA Type C meeting feedback confirmed support for 505(b)(2) regulatory pathway.
- Full UK regulatory and ethical approvals received (MHRA, HRA, WREC) — November 2025.
- FDA Commissioner's National Priority Voucher (CNPV) application filed — November 2025.
- Enrollment of all 90 patients COMPLETED — December 2025.
- Topline results expected Q1 2026. End-of-Phase 2 (EOP2) FDA meeting planned for H1 2026.
Source: Medicus Pharma Q4 2025 Corporate Presentation
BCC Market Opportunity: Basal cell carcinoma is the most common and fastest-growing cancer globally, with more than 5 million cases annually in the United States alone. BCC procedures are projected to grow at 4% per annum reaching 6 million procedures in 2030, representing a market size in excess of US$15 billion annually according to an independent commercial opportunity assessment cited in the company's corporate presentation. SkinJect's D-MNA addresses an estimated US$2+ billion annual market opportunity.
About Teverelix — The Prostate Cancer Opportunity
Antev Ltd., a wholly owned subsidiary of Medicus acquired in August 2025 with Maxim Group LLC acting as exclusive financial advisor, is a clinical-stage biotech company developing Teverelix, a next-generation long-acting gonadotropin-releasing hormone (GnRH) antagonist.
Teverelix is being developed as a potentially first-in-market product for advanced prostate cancer (APC) patients with high cardiovascular risk, and for patients with acute urinary retention relapse (AURr) — collectively representing an estimated ~US$6 billion in potential market opportunity according to the company. The U.S. APC market alone is estimated at more than US$4 billion annually.
Unlike GnRH agonists, which can cause an initial surge in testosterone levels (known as "flare"), Teverelix directly suppresses sex hormone production without this surge. According to the company, clinical and observational data indicate that patients with pre-existing cardiovascular conditions may face significantly higher incidence of major adverse cardiovascular events (MACE) when treated with GnRH agonists compared with GnRH antagonists. An estimated 300,000 to 500,000 men in the United States are living with advanced prostate cancer.
Source: Medicus Pharma Q4 2025 Corporate Presentation
Medicus licensed Teverelix from LifeArc and owns exclusive worldwide commercialization rights. The company holds new composition of matter IP in the USA, EU, and Japan through 2039, and Orange Book IP through 2044/45. According to the company's corporate presentation, approximately 400 patients have been included in Teverelix studies to date with multiple peer-reviewed publications.
The 7 Catalysts Driving (Nasdaq: MDCX) To The Top Of Our Watchlist
No. 1 — SkinJect Phase 2 Topline Data Is Due This Quarter — And The Interim Already Showed >60% Clearance.
Medicus completed enrollment of 90 patients in its Phase 2 clinical study (SKNJCT-003) in December 2025. In the company's December 15, 2025 press release — headlined in all caps — it stated: "THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026." The company also stated it will request an End-of-Phase 2 (EOP2) meeting with the FDA in H1 2026.
We are now in Q1 2026. The SKNJCT-003 study is a randomized, double-blind, placebo-controlled, multi-center studyenrolling 90 patients with nodular basal cell carcinoma across nine clinical sites in the United States. The study is designed to evaluate the safety, tolerability, and clinical efficacy of SkinJect's doxorubicin-containing microneedle array (D-MNA).
A previously disclosed interim analysis — conducted after more than 50% of the then-targeted 60 patients had been randomized — showed more than 60% complete clinical clearance in 26 patients. CEO Dr. Raza Bokhari stated in the December 15, 2025 PR: "We are very hopeful that the clinical study report expected in H1 2026 will reaffirm the positively trending preliminary interim data analysis that the Company released earlier this year in Q1 2025 which showed more than 60% clinical clearance in 26 patients."
The company has noted that the findings of the interim analysis are preliminary and may or may not correlate with the findings of the completed study. The FDA has confirmed the company may follow the 505(b)(2) regulatory pathway for SKNJCT-003.
No. 2 — FDA Cleared Teverelix Phase 2b Trial For Advanced Prostate Cancer With High CV Risk.
On February 10, 2026, Medicus announced via Globe Newswire that it received "study may proceed" clearance from the FDA to initiate its Phase 2b dose-optimization study of Teverelix in men with advanced prostate cancer (APC).
The Phase 2b study is an open-label trial enrolling 40 men with advanced prostate cancer appropriate for androgen deprivation therapy (ADT). The study design includes a loading regimen of 180 mg intramuscular (IM) plus two 180 mg subcutaneous (SC) injections (total 540 mg), followed by 360 mg maintenance doses every six weeks for approximately 22 weeks of total treatment. The primary endpoint is confirmation of medical castration by Day 29 with sustained testosterone suppression through Day 155. The company stated it is targeting a probability of success exceeding 90% for achieving this endpoint.
Per the company's press release, Medicus has aligned with the FDA on a development indication of "hormone therapy for advanced prostate cancer patients with increased cardiovascular risk." The company has also defined a clear Phase 3 framework and maintains a European clinical trial authorization under CTIS for global development.
No. 3 — Management Has Nearly $14 Million Of Personal Capital On The Line At $4/Share.
In a February 12, 2026 press release distributed via ACCESS Newswire referencing a live Bloomberg World interview conducted on February 10, 2026 between CEO Dr. Raza Bokhari and Bloomberg anchor Matt Miller, the company stated that leadership has committed nearly $14 million of personal capital at $4 per share toward advancing its pipeline.
With shares recently trading around $1.53, that represents a commitment at roughly 2.6x the current market price — suggesting significant personal conviction in the company's direction.
No. 4 — A Micro-Cap With 15.4% Institutional Ownership And 6.4% Short Interest.
As of March 1, 2026, MDCX has a float of approximately 17.15 million shares with total shares outstanding of approximately 25.55 million, according to Dilution Tracker data. The company's market capitalization stands at approximately $39.9 million with an enterprise value of $32.9 million and estimated net cash of $0.27 per share, placing it firmly in micro-cap territory.
Institutional ownership sits at 15.4% and short interest is reported at 6.4%. A micro-cap biotech with an imminent binary catalyst (Phase 2 data readout), meaningful institutional presence, and a notable short position could create conditions for heightened volatility if significant news emerges.
No. 5 — Analyst Targets Average $23.50 — Significant Potential Upside From Current Levels.
According to data reported by StockAnalysis.com, MDCX currently has a consensus "Strong Buy" rating from 2 analysts with an average 12-month price target of $23.50. With shares trading at approximately $1.53 as of March 1, 2026, that target represents substantial potential upside. The high target of $27.00 is attributed to Jason Kolbert of D. Boral Capital, with Jason McCarthy of Maxim Group setting a $20.00 target. MarketBeat has reported up to 6 price target entries for MDCX.
Analyst price targets are opinions, not guarantees, and actual results may differ materially. However, the spread between the current trading price and published analyst targets is notable.
No. 6 — Teverelix Royalty Reduced From ~4% To 2%, Improving Partnering Appeal.
On January 22, 2026, Medicus announced via Globe Newswire that its subsidiary Antev Ltd. entered into Amendment No. 3 to its license agreement with LifeArc relating to Teverelix. Under the amended agreement, the royalty rate payable on worldwide net sales of Teverelix was reduced from approximately ~4% to 2%, with the royalty term clarified on a country-by-country basis in line with standard industry practice.
Per the press release, the amendment does not alter the scope of the license, the underlying intellectual property, or the respective development responsibilities. Medicus retains exclusive worldwide rights, sublicensing ability, and IP ownership of all Medicus-developed improvements. A cleaner, lower royalty burden could make Teverelix more attractive in any future partnering or licensing negotiation with larger pharmaceutical companies.
No. 7 — CEO Featured On Bloomberg, Signed 6-Part National Media Series, Rang Nasdaq Bell.
The company has significantly increased its public visibility in recent weeks:
- February 10, 2026: CEO Dr. Raza Bokhari appeared live on Bloomberg World with anchor Matt Miller, discussing AI-driven drug development strategy and upcoming Phase 2 catalysts.
- February 10, 2026: Medicus signed a six-part media series with New to The Street, the nationally syndicated television and digital media platform, to elevate visibility with institutional investors and the healthcare community.
- January 22-23, 2026: Medicus rang the Nasdaq Opening Bell at Times Square to celebrate its one-year anniversary as a Nasdaq-listed company.
- January 12-14, 2026: Dr. Bokhari presented at Biotech Showcase 2026 in San Francisco and held one-on-one meetings with institutional investors and prospective partners.
- January 12, 2026: Teverelix Phase 1 clinical data accepted for e-Poster presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting, April 22-24, 2026 in Las Vegas.
(Nasdaq: MDCX) Recap — These 7 Catalysts Lead The Way
- No. 1 — SkinJect Phase 2 Topline Data Due This Quarter — Interim Showed >60% Clearance.
- No. 2 — FDA Cleared Teverelix Phase 2b Trial For Advanced Prostate Cancer.
- No. 3 — Management Has Nearly $14 Million Of Personal Capital Committed At $4/Share.
- No. 4 — Micro-Cap With 15.4% Institutional Ownership And 6.4% Short Interest.
- No. 5 — Analyst Targets Average $23.50 — Significant Upside From Current Levels.
- No. 6 — Teverelix Royalty Cut To 2% Improves Partnering Appeal.
- No. 7 — Bloomberg, Nasdaq Bell, 6-Part Media Series — Visibility Is Accelerating.
Medicus Pharma Ltd. (Nasdaq: MDCX) has taken over our entire watchlist heading into what could be its most pivotal quarter yet. We will be watching closely. Updates to follow.
Sincerely,
TopStocks.com